Limits...
Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.

Okuda Y, Omoto S, Taniura T, Shouzu A, Nomura S - Int J Gen Med (2016)

Bottom Line: Teneligliptin therapy significantly reduced plasma levels of sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly decreased only at 6 months.The reduction in sP-selectin, PDMPs, and PAI-1 was more significant in HD patients than in non-HD patients.By modulating PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be beneficial in the primary prevention of CVD in patients with T2DM on HD.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine, Meisei Memorial Hospital, Osaka, Japan.

ABSTRACT

Background: Cardiovascular disease (CVD) is the main cause of death among hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving HD treatment are poorly understood. To determine whether teneligliptin has anti-CVD properties, we assessed its effects on soluble P-selectin (sP-selectin), platelet-derived microparticles (PDMPs), plasminogen activator inhibitor 1 (PAI-1), soluble E-selectin (sE-selectin), soluble vascular adhesion molecule 1 (sVCAM-1), and adiponectin plasma levels in HD and non-HD patients with T2DM.

Methods: Patients with T2DM eligible for teneligliptin monotherapy or combination therapy (eg, teneligliptin plus a sulfonylurea) were administered teneligliptin (20 mg/d) once daily for 6 months. Plasma levels of sP-selectin, PDMPs, PAI-1, sE-selectin, sVCAM-1, and adiponectin were measured by enzyme-linked immunosorbent assay at baseline and after 3 months and 6 months of treatment.

Results: Teneligliptin therapy significantly reduced plasma levels of sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly decreased only at 6 months. The reduction in sP-selectin, PDMPs, and PAI-1 was more significant in HD patients than in non-HD patients. However, the improvement in adiponectin levels was unchanged with HD treatment.

Conclusion: By modulating PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be beneficial in the primary prevention of CVD in patients with T2DM on HD.

No MeSH data available.


Related in: MedlinePlus

Changes in sP-selectin (A), PDMP (B), PAI-1 (C), HbA1c (D), and adiponectin (E) in response to treatment with teneligliptin of patients with diabetes with and without hemodialysis.Notes: Bars show the mean ± SD. P-values are for comparison with each baseline parameter (0 M vs 3 M and 0 M vs 6 M). ANOVA was used to analyze differences between HD and non-HD patients.Abbreviations: HbA1c, hemoglobin A1c; sP-selectin, soluble P-selectin; PDMP, platelet-derived microparticle; PAI-1, plasminogen activator inhibitor; HD, hemodialysis; 0 M, 0 months (baseline); 3 M, 3 months after treatment; 6 M, 6 months after treatment; NS, not significant; ANOVA, analysis of variance; SD, standard deviation.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4835142&req=5

f2-ijgm-9-065: Changes in sP-selectin (A), PDMP (B), PAI-1 (C), HbA1c (D), and adiponectin (E) in response to treatment with teneligliptin of patients with diabetes with and without hemodialysis.Notes: Bars show the mean ± SD. P-values are for comparison with each baseline parameter (0 M vs 3 M and 0 M vs 6 M). ANOVA was used to analyze differences between HD and non-HD patients.Abbreviations: HbA1c, hemoglobin A1c; sP-selectin, soluble P-selectin; PDMP, platelet-derived microparticle; PAI-1, plasminogen activator inhibitor; HD, hemodialysis; 0 M, 0 months (baseline); 3 M, 3 months after treatment; 6 M, 6 months after treatment; NS, not significant; ANOVA, analysis of variance; SD, standard deviation.

Mentions: We divided patients with diabetes into two subgroups according to whether they were receiving HD treatment or not. HD patients showed significant reductions in plasma concentrations of sP-selectin, PDMPs, and PAI-1 relative to baseline (P<0.01 for each; Figure 2A–C), and all three concentrations were significantly lower in HD than in non-HD after 3 months and 6 months of teneligliptin treatment (two-factor analysis of variance; P<0.05 each). However, there were no significant differences in HbA1c and adiponectin levels between HD and non-HD patients (Figure 2D and E).


Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.

Okuda Y, Omoto S, Taniura T, Shouzu A, Nomura S - Int J Gen Med (2016)

Changes in sP-selectin (A), PDMP (B), PAI-1 (C), HbA1c (D), and adiponectin (E) in response to treatment with teneligliptin of patients with diabetes with and without hemodialysis.Notes: Bars show the mean ± SD. P-values are for comparison with each baseline parameter (0 M vs 3 M and 0 M vs 6 M). ANOVA was used to analyze differences between HD and non-HD patients.Abbreviations: HbA1c, hemoglobin A1c; sP-selectin, soluble P-selectin; PDMP, platelet-derived microparticle; PAI-1, plasminogen activator inhibitor; HD, hemodialysis; 0 M, 0 months (baseline); 3 M, 3 months after treatment; 6 M, 6 months after treatment; NS, not significant; ANOVA, analysis of variance; SD, standard deviation.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4835142&req=5

f2-ijgm-9-065: Changes in sP-selectin (A), PDMP (B), PAI-1 (C), HbA1c (D), and adiponectin (E) in response to treatment with teneligliptin of patients with diabetes with and without hemodialysis.Notes: Bars show the mean ± SD. P-values are for comparison with each baseline parameter (0 M vs 3 M and 0 M vs 6 M). ANOVA was used to analyze differences between HD and non-HD patients.Abbreviations: HbA1c, hemoglobin A1c; sP-selectin, soluble P-selectin; PDMP, platelet-derived microparticle; PAI-1, plasminogen activator inhibitor; HD, hemodialysis; 0 M, 0 months (baseline); 3 M, 3 months after treatment; 6 M, 6 months after treatment; NS, not significant; ANOVA, analysis of variance; SD, standard deviation.
Mentions: We divided patients with diabetes into two subgroups according to whether they were receiving HD treatment or not. HD patients showed significant reductions in plasma concentrations of sP-selectin, PDMPs, and PAI-1 relative to baseline (P<0.01 for each; Figure 2A–C), and all three concentrations were significantly lower in HD than in non-HD after 3 months and 6 months of teneligliptin treatment (two-factor analysis of variance; P<0.05 each). However, there were no significant differences in HbA1c and adiponectin levels between HD and non-HD patients (Figure 2D and E).

Bottom Line: Teneligliptin therapy significantly reduced plasma levels of sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly decreased only at 6 months.The reduction in sP-selectin, PDMPs, and PAI-1 was more significant in HD patients than in non-HD patients.By modulating PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be beneficial in the primary prevention of CVD in patients with T2DM on HD.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine, Meisei Memorial Hospital, Osaka, Japan.

ABSTRACT

Background: Cardiovascular disease (CVD) is the main cause of death among hemodialysis (HD) patients. The effects of the dipeptidyl peptidase-4 inhibitor teneligliptin on CVD-related biomarkers in patients with type 2 diabetes mellitus (T2DM) receiving HD treatment are poorly understood. To determine whether teneligliptin has anti-CVD properties, we assessed its effects on soluble P-selectin (sP-selectin), platelet-derived microparticles (PDMPs), plasminogen activator inhibitor 1 (PAI-1), soluble E-selectin (sE-selectin), soluble vascular adhesion molecule 1 (sVCAM-1), and adiponectin plasma levels in HD and non-HD patients with T2DM.

Methods: Patients with T2DM eligible for teneligliptin monotherapy or combination therapy (eg, teneligliptin plus a sulfonylurea) were administered teneligliptin (20 mg/d) once daily for 6 months. Plasma levels of sP-selectin, PDMPs, PAI-1, sE-selectin, sVCAM-1, and adiponectin were measured by enzyme-linked immunosorbent assay at baseline and after 3 months and 6 months of treatment.

Results: Teneligliptin therapy significantly reduced plasma levels of sP-selectin, PDMPs, and PAI-1 compared with baseline levels, while significantly increasing adiponectin levels. sE-selectin and sVCAM-1 levels were significantly decreased only at 6 months. The reduction in sP-selectin, PDMPs, and PAI-1 was more significant in HD patients than in non-HD patients. However, the improvement in adiponectin levels was unchanged with HD treatment.

Conclusion: By modulating PDMPs or PAI-1, teneligliptin shows an antiatherothrombotic effect that may be beneficial in the primary prevention of CVD in patients with T2DM on HD.

No MeSH data available.


Related in: MedlinePlus